Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 15/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 14/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 14/20 | 0.55 |
| ▸ | F10 | P00742 | 7/20 | 0.54 |
| ▸ | PLG | P00747 | 2/20 | 0.54 |
| ▸ | PLAT | P00750 | 2/20 | 0.54 |
| ▸ | F7 | P08709 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5885767 | 0.88 | F2 (0.57) | F2PRSS1PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL5885688 | 0.87 | F2 (0.56) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5886150 | 0.80 | F2 (0.54) | F2PRSS1PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL5886180 | 0.79 | F2 (0.53) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5885775 | 0.79 | USP30 (0.37) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5885744 | 0.76 | ACACB (0.40) | F2PRSS1PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL5885692 | 0.76 | ACACB (0.40) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5885649 | 0.74 | F2 (0.77) | F2PRSS1PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL5885248 | 0.73 | F2 (0.76) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL7059603 | 0.73 | PRSS1 (0.62) | F2PRSS1PRSS2PRSS3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | claimed |
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | F2 1/4885PRSS1 204/4885PRSS2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.